Safety of PPAR agonists.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. Efficacy of antihyperglycemic therapies on cardiovascular and heart failure outcomes: an updated meta-analysis and meta-regression analysis of 35 randomized cardiovascular outcome trials.Cardiovascular diabetology · 2023
   Pooled it
2. From Current Therapeutics to Multitarget Ligands: A Review of Diabetes Pharmacological Treatments.Pharmaceutics · 2025
   Review
3. KDOQI US Commentary on the KDIGO 2020 Clinical Practice Guideline for Diabetes Management in CKD.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2022
   Article
4. The Gut-Lung Axis in Cystic Fibrosis.Journal of bacteriology · 2021
   Review
5. Diallyl Biphenyl-Type Neolignans Have a Pharmacophore of PPARα/γ Dual Modulators.Biomolecules & therapeutics · 2020
   Article
6. Diverting epithelial-to-mesenchymal transition to transform cancer cells to adipocytes: A promising strategy to stop metastasis.Metabolism open · 2019
   Article
7. Pioglitazone Improves Left Ventricular Diastolic Function in Subjects With Diabetes.Diabetes care · 2017
   Article
8. Endothelial LRP1 regulates metabolic responses by acting as a co-activator of PPARγ.Nature communications · 2017
   Article
9. New Pharmacological Agents to Aid Smoking Cessation and Tobacco Harm Reduction: What Has Been Investigated, and What Is in the Pipeline?CNS drugs · 2016
   Review
10. Gliptins and Cardiovascular Outcomes: A Comparative and Critical Analysis after TECOS.Journal of diabetes research · 2016
    Review
11. Cardiometabolic interventions - focus on transcriptional regulators.The European journal of cardiovascular medicine · 2013
    Article
12. Modulating peroxisome proliferator-activated receptors for therapeutic benefit? Biology, clinical experience, and future prospects.American heart journal · 2012
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as